盈利预期修正
Search documents
Electronic Arts (EA) Q1 Earnings and Revenues Beat Estimates
ZACKS· 2025-07-29 22:21
Core Viewpoint - Electronic Arts (EA) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.1 per share, but down from $0.52 per share a year ago, indicating a significant earnings surprise of +150.00% [1][2] Financial Performance - EA's revenues for the quarter ended June 2025 were $1.3 billion, surpassing the Zacks Consensus Estimate by 4.65% and showing a year-over-year increase from $1.26 billion [2] - Over the last four quarters, EA has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Performance and Outlook - EA shares have increased approximately 3.9% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The future performance of EA's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.08 on revenues of $1.99 billion, and for the current fiscal year, it is $8.22 on revenues of $7.88 billion [7] - The estimate revisions trend for EA was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The gaming industry, to which EA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a positive outlook compared to the bottom 50% [8] - The performance of EA's stock may also be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]
PPG Industries (PPG) Meets Q2 Earnings Estimates
ZACKS· 2025-07-29 22:16
Group 1: Earnings Performance - PPG Industries reported quarterly earnings of $2.22 per share, matching the Zacks Consensus Estimate, but down from $2.5 per share a year ago [1] - The company had revenues of $4.2 billion for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.53%, but down from $4.79 billion year-over-year [2] - PPG Industries has surpassed consensus EPS estimates only once in the last four quarters [1] Group 2: Stock Performance and Outlook - PPG Industries shares have declined approximately 4.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $2.12 for the next quarter and $7.89 for the current fiscal year [4][7] - The Zacks Rank for PPG Industries is currently 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Chemical - Specialty industry, to which PPG Industries belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]
Starbucks (SBUX) Misses Q3 Earnings Estimates
ZACKS· 2025-07-29 22:16
Starbucks (SBUX) came out with quarterly earnings of $0.5 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -23.08%. A quarter ago, it was expected that this coffee chain would post earnings of $0.49 per share when it actually produced earnings of $0.41, delivering a surprise of -16.33%. Over the last four quarters, the compa ...
Booking Holdings (BKNG) Beats Q2 Earnings and Revenue Estimates
ZACKS· 2025-07-29 22:11
分组1 - Booking Holdings reported quarterly earnings of $55.4 per share, exceeding the Zacks Consensus Estimate of $50.91 per share, and up from $41.9 per share a year ago, representing an earnings surprise of +8.82% [1] - The company posted revenues of $6.8 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.56%, compared to $5.86 billion in the same quarter last year [2] - Booking Holdings has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 14.3% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $95.90 on revenues of $8.69 billion, and for the current fiscal year, it is $219.50 on revenues of $25.86 billion [7] - The Internet - Commerce industry, to which Booking Holdings belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8]
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2025-07-29 22:11
Company Performance - AtriCure reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.17 per share a year ago, resulting in an earnings surprise of +86.67% [1] - The company achieved revenues of $136.14 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.61% and showing a year-over-year increase from $116.27 million [2] - Over the last four quarters, AtriCure has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - AtriCure shares have increased approximately 8.7% since the beginning of the year, slightly outperforming the S&P 500's gain of 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $129.12 million, and for the current fiscal year, it is -$0.50 on revenues of $522.61 million [7] Industry Context - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of AtriCure's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
Eagle Bancorp Montana, Inc. (EBMT) Meets Q2 Earnings Estimates
ZACKS· 2025-07-29 16:11
Core Insights - Eagle Bancorp Montana, Inc. (EBMT) reported quarterly earnings of $0.41 per share, matching the Zacks Consensus Estimate and showing an increase from $0.22 per share a year ago [1] - The company achieved revenues of $22.95 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.28% and up from $19.9 million year-over-year [2] - The stock has gained approximately 7.1% since the beginning of the year, compared to an 8.6% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.45, with expected revenues of $22.5 million, and for the current fiscal year, the EPS estimate is $1.70 on revenues of $87.5 million [7] - The estimate revisions trend for Eagle Bancorp Montana was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Banks - Midwest industry, to which Eagle Bancorp Montana belongs, is currently ranked in the top 16% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]
TriMas (TRS) Beats Q2 Earnings and Revenue Estimates
ZACKS· 2025-07-29 14:10
Company Performance - TriMas reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, and up from $0.43 per share a year ago, indicating a positive earnings surprise of +22.00% [1][2] - The company achieved revenues of $274.76 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.93%, compared to $240.5 million in the same quarter last year [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.52 on revenues of $257.51 million, and for the current fiscal year, it is $1.81 on revenues of $980.07 million [8] - The estimate revisions trend for TriMas was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [7] Industry Context - TriMas operates within the Zacks Metal Products - Procurement and Fabrication industry, which is currently ranked in the bottom 30% of over 250 Zacks industries, suggesting potential challenges ahead [9] - The performance of TriMas may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]
Commvault Systems (CVLT) Q1 Earnings and Revenues Surpass Estimates
ZACKS· 2025-07-29 13:56
Core Insights - Commvault Systems (CVLT) reported quarterly earnings of $1.01 per share, exceeding the Zacks Consensus Estimate of $0.97 per share, and up from $0.85 per share a year ago, representing an earnings surprise of +4.12% [1] - The company achieved revenues of $281.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.96%, compared to $224.67 million in the same quarter last year [2] - Commvault has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $272.17 million, while for the current fiscal year, the estimate is $4.14 on revenues of $1.14 billion [7] - The favorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 1 (Strong Buy) for Commvault, suggesting expected outperformance in the near future [6] Industry Context - The Computer - Software industry, to which Commvault belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Repligen (RGEN) Lags Q2 Earnings Estimates
ZACKS· 2025-07-29 13:46
Core Viewpoint - Repligen reported quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.40 per share, but showing an increase from $0.33 per share a year ago, resulting in an earnings surprise of -7.50% [1][2] Financial Performance - The company posted revenues of $182.37 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 3.56% and up from $154.07 million year-over-year [2] - Over the last four quarters, Repligen has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Repligen shares have declined approximately 16.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $175.08 million, and for the current fiscal year, it is $1.68 on revenues of $710.85 million [7] - The trend of estimate revisions for Repligen was favorable ahead of the earnings release, suggesting potential positive movements in stock price [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
ZACKS· 2025-07-29 13:41
Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $156.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.92%. This compares to year-ago revenues of $108.63 million. The company has topped consensus revenue estimates four times over the last four quarters. Kiniksa Pharmaceuticals International, plc ( ...